ValiRx plc (GB:VAL) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ValiRx PLC has extended its exclusivity agreement with TheoremRx Inc until the end of 2024, in exchange for a 0.5% equity stake. This extension aims to support TheoremRx in securing financing necessary for the sublicensing of ValiRx’s VAL201 cancer therapeutic. Investors are watching closely as the deal remains non-binding and dependent on successful financial arrangements.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.
